Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001580642-24-006951
Filing Date
2024-11-14
Accepted
2024-11-14 12:18:08
Documents
2
Group Members
FINNY KURUVILLA, M.D. PH. D.ROBIN C. JOHN

Document Format Files

Seq Description Document Type Size
1 SC 13G/A eventide_celldex-sc13g.htm SC 13G/A 54261
2 GRAPHIC image_001.gif GRAPHIC 97
  Complete submission text file 0001580642-24-006951.txt   56540
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 241459279
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address ONE INTERNATIONAL PLACE SUITE 4210 BOSTON MA 02110
Business Address ONE INTERNATIONAL PLACE SUITE 4210 BOSTON MA 02110 877-771-3836
EVENTIDE ASSET MANAGEMENT, LLC (Filed by) CIK: 0001442891 (see all company filings)

EIN.: 262508416 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A